<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>18349856</Do_id>
  <Journal>Nature clinical practice. Oncology</Journal>
  <Doc_title>Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?</Doc_title>
  <Doc_abstract>None</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Benzamides;Chemotherapy, Adjuvant;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Piperazines;Pyrimidines;Randomized Controlled Trials as Topic</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapeutic use;drug therapy;surgery;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
